Nebivolol is indicated for the following conditions-

• Hypertension
• Chronic heart failure (CHF) :Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients ≥ 70 years.

Hypertension (Hight Blood Pressure)

Heart Failure

The dose of Nebivolol must be tailored to the patient's specific needs. The suggested initial dose for most individuals is 5 mg once daily, with or without food, as monotherapy or in combination with other medications. The dose can be increased up to 40 mg at 2-week intervals for people who require further blood pressure lowering. It's unlikely that a more frequent dosing schedule will help.

Patients with renal impairment:
The recommended starting dose for people with renal insufficiency is 2.5 mg per day. The daily dose can be increased to 5 mg if necessary.

Patients with hepatic impairment:
There is a scarcity of data in patients with hepatic insufficiency or reduced liver function. As a result, Nebivolol should not be used in these individuals.

Geriatric patients:

The suggested beginning dose for patients over the age of 65 is 2.5 mg per day. The daily dose can be increased to 5 mg if necessary. However, due to the lack of experience with patients above the age of 75, vigilance should be exercised and these individuals constantly watched.

Common side effects associated with Nebivolol are-

• Headache
• Dizziness
• Paresthesia
• Constipation
• Nausea
• Diarrhea
• Asthenia
• Edema

Headache	Dizziness	Edema
Asthenia	Nausea	Diarrhea

• Patients with coronary artery disease have experienced severe worsening of angina, myocardial infarction, and ventricular arrhythmias after abruptly discontinuing -blocker medication.
• Beta-blockers should not be given to people with bronchospastic disorders in general.
• Some hypoglycemia symptoms, particularly tachycardia, may be obscured by -blockers. Nonselective blockers may increase the severity of insulin-induced hypoglycemia and prolong the time it takes for serum glucose levels to return to normal.
• In patients with significant renal impairment, nebivolol clearance is reduced.
• In patients with significant hepatic impairment, nebivolol metabolism is reduced.